Howard C. Herrmann, MD, principal investigator of the SMART trial, discussed his team's research on self-expanding vs. balloon-expandable TAVR valves in patients with small annuli. 

While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

The Dual Energy THERMOCOOL SMARTTOUCH SF Catheter is the first dual energy pulsed field (PF) ablation / radiofrequency (RF) ablation catheter integrated with a PF and RF ablation index.

An independent heart team blinded to ICA results was able to deliver helpful guidance for CABG procedures for 99.1% of patients using just CCTA and FFR_CT alone. This approach is safe and feasible, researchers wrote, and the next step is to gather additional data. 

"We were thrilled with the meeting and the attendance," ACC President Cathie Biga, RN, told Cardiovascular Business.

The anticoagulant was originally developed for patients with end-stage renal disease and atrial fibrillation. 

U.S. Senator Elizabeth Warren, an outspoken critic of private equity's influence, praised the group's efforts. "Together, we’re taking on this trillion-dollar, behemoth industry that’s hurting working people and sucking money out of the rest of the economy," she said. 

The PREVENT study, presented at ACC.24, examined more than 1,600 patients with high-risk plaques treated with either preventive PCI or medical therapy alone. Outcomes were much better for the PCI group after two years, but the findings may lead to more questions than answers. 

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

"This was an unneeded burden, which was solely adding to the administrative hassles of medicine," said American Society of Nuclear Cardiology President Larry Phillips.